Findings

What do systematic reviews say?

5 questions · 5 findings · 2 reviews · Infectious Diseases

Sort:Best matchNewest Highest certainty Download CSV

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 2 · 40%Low 1 · 20%Moderate 1 · 20%High 1 · 20%

Intermittent short‐course anti‐TB regimens vs daily anti‐TB regimens

Treatment‐limiting adverse events · Children with TB1

It is very uncertain whether intermittent short‐course anti‐TB regimens changes treatment‐limiting adverse events compared with daily anti‐TB regimens (very low certainty).

1 finding from 1 review

Intermittent versus daily therapy for treating tuberculosis in children 2014 · Cochrane Headline outcomes only
RR 0.4 [0.06, 2.6]
4 studies · 441 participants
Very low

Rifampicin plus pyrazinamide vs isoniazid

Treatment‐limiting adverse events · HIV‐negative people at risk of TB infection1

Rifampicin plus pyrazinamide leads to higher treatment‐limiting adverse events compared with isoniazid (high certainty).

1 finding from 1 review

Rifamycins (rifampicin, rifabutin and rifapentine) compared to isoniazid for preventing tuberculosis in HIV‐negative… 2013 · Cochrane Headline outcomes only
RR 3.61 [1.82, 7.19]
2 studies · 368 participants
High

Rifapentine plus isoniazid weekly vs isoniazid

Treatment‐limiting adverse events · HIV‐negative people at risk of TB infection1

Rifapentine plus isoniazid weekly probably leads to higher treatment‐limiting adverse events compared with isoniazid daily (moderate certainty).

1 finding from 1 review

Rifamycins (rifampicin, rifabutin and rifapentine) compared to isoniazid for preventing tuberculosis in HIV‐negative… 2013 · Cochrane Headline outcomes only
RR 1.32 [1.07, 1.64]
1 study · 7731 participants
Moderate

Rifampicin vs isoniazid

Treatment‐limiting adverse events · HIV‐negative people at risk of TB infection1

It is very uncertain whether rifampicin changes treatment‐limiting adverse events compared with isoniazid (very low certainty).

1 finding from 1 review

Rifamycins (rifampicin, rifabutin and rifapentine) compared to isoniazid for preventing tuberculosis in HIV‐negative… 2013 · Cochrane Headline outcomes only
RR 0.48 [0.23, 1]
4 studies · 1674 participants
Very low

Rifampicin plus isoniazid vs isoniazid

Treatment‐limiting adverse events · HIV‐negative people at risk of TB infection1

Rifampicin plus isoniazid showed no clear difference in treatment‐limiting adverse events compared with isoniazid (low certainty).

1 finding from 1 review

Rifamycins (rifampicin, rifabutin and rifapentine) compared to isoniazid for preventing tuberculosis in HIV‐negative… 2013 · Cochrane Headline outcomes only
RR 1.16 [0.74, 1.82]
2 studies · 536 participants
Low